Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 14;7(5):931–945. doi: 10.1080/19420862.2015.1055442

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

© Eli Lilly and Company

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 8. — In vivo mechanism of action in Colo-205 xenograft model. (A) Average signal of total human IGF-IR from lysates of excised tumor, (B) human VEGF concentration (pg/ml) from mouse plasma and (C) Mouse VEGF concentration (pg/ml) from mouse plasma after 2- and 7-day treatments with saline, IR mAb, FcD2 and ID2 were determined by electrochemiluminescent assay. Significant differences in mean (p < 0.05, n = 5) are indicated (a vs Saline; b vs IR mAb; c vs FcD2). (D) Percentage of nuclei with positive immunohistochemistry staining for cleaved caspase-3 from representative tumor tissue after 2-day treatment was compared and plotted as mean ± SEM (n = 5). ID2 treated group had significantly increased cleaved caspase-3 activity compared to saline control (p = 0.0035, one way ANOVA), IR mAb (p = 0.0041, one way ANOVA) and FcD2 (p = 0.0254, one way ANOVA). All charts were generated and statistical analyses were performed with SigmaPlot or Graphpad Prism 6.